Incidence of extended-spectrum-β-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates that test susceptible to Cephalosporins and aztreonam by the revised CLSI breakpoints

Journal of Clinical Microbiology

Volumn 52, Issue 7, 2014, Pages 2653-2655

  McWilliams, Carla S ^a,c   Condon, Susan ^a   Schwartz, Rebecca M ^a,b   Ginocchio, Christine C ^a,b  

^a Northwell Health   (United States)

^b DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^c LUTHERAN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZTREONAM; CARBAPENEM; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CLAVULANIC ACID; ANTIINFECTIVE AGENT; BETA LACTAMASE;

ANALYTICAL PARAMETERS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; DRUG EFFICACY; ENTEROBACTERIACEAE INFECTION; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ESCHERICHIA COLI; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING KLEBSIELLA PNEUMONIAE; INCIDENCE; INOCULATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; REVISED CLSI BREAKPOINT; DRUG EFFECTS; ENZYMOLOGY; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; HUMAN; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; SECRETION (PROCESS);

ANTI-BACTERIAL AGENTS; AZTREONAM; BETA-LACTAMASES; CEPHALOSPORINS; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; HUMANS; INCIDENCE; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS;

EID: 84903795633     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.03613-13     Document Type: Article

References (18)

1. Bradford P. 2001. Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin. Microbiol. Rev. 14:933-951. http://dx.doi.org/10.1128/CMR.14.4. 933-951.2001. (Pubitemid 32979636)
2. Thomson KS. 2010. Extended-spectrum beta-lactamase, AmpC, and carbapenemase issues. J. Clin. Microbiol. 48:1019-1025. http://dx.doi.org/10. 1128/JCM.00219-10.
3. Ben-Ami R, Rodríguez-Baño J, Arslan H, Pitout JD, Quentin C, Calbo ES, Azap OK, Arpin C, Pascual A, Livermore DM, Garau J, Carmeli Y. 2009. A multinational survey of risk factors for infection with extendedspectrum beta-lactamase producing Enterobacteriaceae in nonhospitalized patients. Clin. Infect. Dis. 49:682-690. http://dx.doi.org/10.1086/604713.
4. Centers for Disease Control and Prevention. 2013. Antibiotic resistance threats in the United States, 2013. Centers for Disease Control and Prevention, Atlanta, GA. http://www.cdc.gov/drugresistance/threat-report-2013.
5. Paterson DL, Bonomo RA. 2005. Extended-spectrum beta-lactamases: a clinical update. Clin. Microbiol. Rev. 18:657-686. http://dx.doi.org/10.1128/ CMR.18.4.657-686.2005.
6. Clinical and Laboratory Standards Institute. 2010. Performance standards for antimicrobial susceptibility testing; 20th informational supplement. CLSI document M100-S20. Clinical and Laboratory Standards Institute, Wayne, PA.
7. Clinical and Laboratory Standards Institute. 2014. Performance standards for antimicrobial susceptibility testing; 21st informational supplement. CLSI document M100-S24. Clinical and Laboratory Standards Institute, Wayne, PA.
8. Thomson KS, Moland ES. 2001. Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamaseproducing Enterobacteriaceae. Antimicrob. Agents Chemother. 45:3548-3554. http://dx.doi.org/10.1128/AAC.45.12.3548-3554.2001. (Pubitemid 33107876)
9. Kristo I, Pitiriga V, Poulou A, Zarkotou O, Kimouli M, Pournaras S, Tsakris A. 2013. Susceptibility patterns to extended-spectrum cephalosporins among Enterobacteriaceae harbouring extended-spectrum β-lactamases using the updated Clinical and Laboratory Standards Institute interpretive criteria. Int. J. Antimicrob. Agents 41:383-387. http://dx.doi.org/10.1016/j.ijantimicag. 2012.12.003.
10. Wang P, Hu F, Xiong Z, Ye X, Zhu D, Wang YF, Wang M. 2011. Susceptibility of ESBL-producing Enterobacteriaceae with the new CLSI breakpoints. J. Clin. Microbiol. 49:3127-3131. http://dx.doi.org/10.1128/JCM.00222-11.
11. Nguyen HM, Shier KL, Graber CJ. 2014. Determining a clinical framework for use of cefepime and β-lactam/β-lactamase inhibitors in the treatment of infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae. J. Antimicrob. Chemother. 69:871-880. http://dx.doi.org/10. 1093/jac/dkt450.
12. Ambrose PG, Bhavnani SM, Jones RN. 2003. Pharmacokinetics/ pharmacodynamics of cefepime and piperacillin-tazobactam against Escherichia coli and Klebsiella pneumoniae strains producing extendedspectrum β-lactamases: report from the ARREST program. Antimicrob. Agents Chemother. 47:1643-1646. http://dx.doi.org/10.1128/AAC.47.5.1643-1646.2003. (Pubitemid 36548549)
13. Chopra T, Marchaim D, Veltman Johnson JP, Zhao JJ, Tansek R, Hatahet D, Chaudhry K, Pogue JM, Rahbar H, Chen TY, Truong T, Rodriguez V, Ellsworth J, Bernabela L, Bhargava A, Yousuf A, Alangaden G, Kaye KS. 2012. Impact of cefepime therapy on mortality among patients with bloodstream infections caused by extended-spectrum-β-lactamase-producing Klebsiella pneumoniae and Escherichia coli. Antimicrob. Agents Chemother. 56:3936-3942. http://dx.doi.org/10.1128/AAC.05419-11.
14. Falagas ME, Tansarli GS, Rafailidis PI, Kapaskelis A, Vardakas KZ. 2012. Impact of antibiotic MIC on infection outcome in patients with susceptible Gram-negative bacteria: a systematic review and metaanalysis. Antimicrob. Agents Chemother. 56:4214-4222. http://dx.doi.org/10.1128/AAC.00663-12.
15. Bhat SV, Peleg AY, Lodise TP, Jr, Shutt KA, Capitano B, Potoski BA, Paterson DL. 2007. Failure of current cefepime breakpoints to predict clinical outcomes of bacteremia caused by Gram-negative organisms. Antimicrob. Agents Chemother. 51:4390-4395. http://dx.doi.org/10.1128/AAC.01487-06. (Pubitemid 350209894)
16. Paterson DL, Ko WC, Von Gottberg A, Casellas JM, Mulazimoglu L, Klugman KP, Bonomo RA, Rice LB, McCormack JG, Yu VL. 2001. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum βlactamases: implications for the clinical microbiology laboratory. J. Clin. Microbiol. 39:2206-2212. http://dx.doi.org/10. 1128/JCM.39.6.2206-2212.2001. (Pubitemid 32531482)
17. Peralta G, Lamelo M, Alvarez-García P, Velasco M, Delgado A, Horcajada JP, Montero M, Roiz MP, Fariñas MC, Alonso J, Martínez LM, Gutiérrez-Macías A, Alava JA, Rodríguez A, Fleites A, Navarro V, Sirvent E, Capdevila JA, SEMI-BLEE Study Group. 2012. Impact of empirical treatment in extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. bacteremia: a multicentric cohort study. BMC Infect. Dis. 12:245. http://dx.doi.org/10.1186/1471-2334-12-245.
18. Lee NY, Lee CC, Huang WH, Tsui KC, Hsueh PR, Ko WC. 2013. Cefepime therapy for monomicrobial bacteremia caused by cefepimesusceptible extended spectrum beta-lactamase-producing Enterobacteriaceae: MIC matters. Clin. Infect. Dis. 56:488-495. http://dx.doi.org/10.1093/cid/cis916.